Partner Anil Shankar was quoted in the Modern Healthcare article, “CMS Should Toss Proposed MFAR Rule, Experts Say,” about CMS’ proposed Medical Fiscal Accountability Rule and how its impairing the ability of states and safety-net providers to respond to the COVID-19 pandemic.
States are largely footing the bill for the many costs associated with treating COVID-19 amid a precipitous drop in tax revenues and a steep increase in unemployment and Medicaid enrollment. Last year, CMS proposed a rule that would increase the transparency of states’ supplemental payments to providers and limit how states can finance their Medicaid programs. While health care experts agree that more accountability is needed, many say CMS’ approach gives the agency too much power and the rule could have fallout. The pandemic has only increased those concerns.
MFAR may further complicate the Medicaid program. “It would be throwing additional fuel on what’s already a burning fire,” Shankar said. He suspects the rule will be back burnered due to the pandemic.
(Subscription required)
States are largely footing the bill for the many costs associated with treating COVID-19 amid a precipitous drop in tax revenues and a steep increase in unemployment and Medicaid enrollment. Last year, CMS proposed a rule that would increase the transparency of states’ supplemental payments to providers and limit how states can finance their Medicaid programs. While health care experts agree that more accountability is needed, many say CMS’ approach gives the agency too much power and the rule could have fallout. The pandemic has only increased those concerns.
MFAR may further complicate the Medicaid program. “It would be throwing additional fuel on what’s already a burning fire,” Shankar said. He suspects the rule will be back burnered due to the pandemic.
(Subscription required)
People
Related News
06 September 2024
In the News
Old Employment Law Principles Can Answer New AI Concerns
The integration of artificial intelligence into the workplace has sparked a flurry of legal and regulatory discussions in recent months.
04 September 2024
In the News
Nathaniel Lacktman Comments on Prospect of Regressive DEA Stance on Telemedicine Prescribing of Controlled Substances
Foley & Lardner LLP partner Nathaniel Lacktman, chair of firm’s national Telemedicine & Digital Health Industry Team and member of the American Telemedicine Association Board of Directors, offered insight on how providers might prepare if the U.S. Drug Enforcement Agency (DEA) issues regressive regulations on telemedicine prescribing in the Modern Healthcare article, “Specter of strict DEA prescribing rule rattles telehealth sector.”
04 September 2024
In the News
Louis Lehot on Biotech IPOs – 'Biotech could have a great fourth quarter'
Foley & Lardner LLP partner Louis Lehot offered insight on the biotech industry’s upcoming initial public offerings in the Bloomberg Law article, “Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch.”